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Objective: As the mean age in patients with non–small cell lung cancer increases,
the proportion of patients with serious comorbidity who are considered for surgical
resection also increases. Patients with non–small cell lung cancer have been shown
to have a higher burden of comorbidity than do patients with tumors of other sites,
such as breast, prostate, colon, and head and neck. The goal of this review was to
determine the impact of comorbidity on postoperative and long-term survival after
surgical resection in patients with stage I non–small cell lung cancer.
Methods: A database analysis of our hospital’s tumor registry included 451 patients
who underwent surgical resection for pathologic stage I non–small cell lung cancer
between January 1, 1994, and December 31, 1999. Comorbidity severity was
prospectively determined with the Kaplan-Feinstein Index. Survival data were col-
lected for each patient from the date of operation, with a mean duration of follow-
up of 35.7 months. Bivariate statistics and Cox proportional hazards model analyses
were used.
Results: The mean age was 64.4 years, and 249 (55%) patients were male. The dis-
tribution of overall comorbidity severity was none, 142 (31.5%); mild, 150 (33.3%);
moderate, 115 (25.5%); and severe, 44 (9.8%). The overall in-hospital mortality
was 2.2% (n = 10/451). There was a nonsignificant trend toward higher hospital
mortality with greater comorbidity: none, 0.7% (n = 1/142); mild, 3.3% (n = 5/150);
moderate, 0.9% (n = 1/115); and severe, 6.8% (n = 3/44, P = .055). Kaplan-Meier
estimated survivals at 3 years for each level of comorbidity were as follows: none,
85.6%; mild, 74.8%; moderate, 68.8%; and severe, 70.0% (P < .002). After adjust-
ment for age, sex, T status, and tumor histologic type, the relative risks of death as
a function of comorbidity were mild, 1.44 (95% confidence interval 0.89-2.34);
moderate, 2.28 (95% confidence interval 1.43-3.65); and severe; 1.94 (95% confi-
dence interval 1.023-3.70).
Conclusions: Comorbidity has a significant impact on survival after surgical resec-
tion of patients with stage I non–small cell lung cancer. These data may help to
explain the lower than expected survival results for patients after surgical resection
for stage I non–small cell lung cancer.
Non–small cell lung cancer (NSCLC) is responsible for more than120,000 deaths per year in the United States.1 Most patients arefirst seen with locally advanced or metastatic NSCLC that is unre-sponsive to chemotherapy and radiation therapy, and these indi-viduals ultimately die of their disease. However, patients with asingle focus of NSCLC that is amenable to complete surgical
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resection have a more favorable prognosis. Actuarial 5-year
survivals among patients with completely resected stage I
and stage II NSCLC are 55% to 75% and 35% to 45%,
respectively.2-5
Many patients with lung cancer have concurrent medical
conditions (comorbidities) that significantly affect overall
health. In addition to other tobacco-associated illnesses,
such as chronic obstructive pulmonary disease, atheroscle-
rotic cardiovascular disease, and head and neck cancer,
patients may have diabetes mellitus, chronic renal insuffi-
ciency, or morbid obesity. These comorbidities often influ-
ence both treatment selection and survival after treatment.
The purpose of this study was to examine the impact of
patient comorbidity on survival after surgical resection of
stage I NSCLC.
Methods
Population Under Study
The Barnes-Jewish Hospital Cancer Registry and the Thoracic
Surgery database were queried, and records of 480 patients who
underwent surgical resection for stage I NSCLC from January 1,
1994, to December 31, 1999, were selected. Of these patients, 451
(94%) had comorbidity severity scores determined prospectively
at the time of diagnosis of NSCLC, and these patients form the
population studied in this analysis.
The surgical pathology reports of all patients selected from this
database query were individually reviewed, and the final patho-
logic staging was assigned according to the 1997 revisions in the
International System for Staging Lung Cancer.5 Only patients with
pathologically staged T1 N0 M0 (stage IA) or T2 N0 M0 (stage
IB) NSCLC tumors were included in the analysis. Patients with
carcinoid tumors, patients who had been previously treated for
lung cancer, and patients who had received preoperative
chemotherapy or radiation therapy were also excluded from this
analysis.
Tumor recurrence, patient survival, and cause of death were
determined for each patient. Follow-up information, including
cause of death, was acquired within the last 6 months for all
patients through clinic follow-up notes, direct patient or family
contact, contact with the patient’s primary care physician, and
review of all death certificates. This study represents a secondary
data analysis of a prospective cohort study. Approval for this study
TABLE 1. Organ systems examined in the modified KFI
Cardiovascular system
Myocardial infarction
Angina or coronary artery disease
Congestive heart failure
Arrhythmia
Hypertension
Venous disease
Peripheral arterial disease
Respiratory system
Restrictive lung disease
Chronic obstructive pulmonary disease
Gastrointestinal system
Hepatic disease
Stomach or intestinal disease
Pancreatic disease
Renal system
End-stage renal disease
Endocrine system
Diabetes mellitus
Neurologic system
Stroke or cerebrovascular accident
Dementia
Paralysis
Neuromuscular disease
Psychiatric system
Rheumatologic system
Immunologic system
AIDS
Malignancy
Solid tumor
Leukemia and myeloma
Lymphoma
Substance abuse
Alcohol
Illicit drugs
Body weight or obesity
TABLE 2. Demographic features and treatment information
for the 451 patients undergoing resection for stage I NSCLC
Gender (No.)
Male 249 (55.2%)
Female 202 (44.8%)
Age (y, mean ± SD) 64.4 ± 10.5
Comorbidity severity (No.)
None 142 (31.5%)
Mild 150 (33.2%)
Moderate 115 (25.5%)
Severe 44 (9.8%)
Type of resection (No.)
Lobectomy 369 (81.8%)
Wedge 32 (7.1%)
Bilobectomy 14 (3.1%)
Pneumonectomy 12 (2.7%)
Segmentectomy 12 (2.7%)
Lobectomy and wedge 6 (1.3%)
Sleeve lobectomy 6 (1.3%)
Histologic type (No.)
Adenocarcinoma 209 (46.3%)
Squamous 176 (39.0%)
Large cell 27 (6.0%)
Bronchoalveolar 23 (5.1%)
Adenosquamous 16 (3.6%)
T status
T1 250 (55.4%)
T2 201 (44.6%)
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was granted from Washington University School of Medicine’s
human studies committee.
Comorbidity Severity
Since 1994, specifically trained cancer registrars have prospec-
tively coded overall severity of comorbidity for patients with can-
cer treated at Barnes-Jewish Hospital, St Louis, Mo, with a
modified version of the Kaplan-Feinstein Index (KFI).6 Minor
modifications to the KFI were made to include diabetes mellitus
and other comorbid conditions not present on the original KFI.
The KFI classifies the pathophysiologic derangement of each
comorbid ailment according to a four-category system (0, 1, 2, 3).
An overall comorbidity score (none, mild, moderate, or severe) is
determined on the basis of the number of ailments and their indi-
vidual degrees of decompensation. The organ systems examined
with the modified KFI are outlined in Table 1. The cancer regis-
trars determined the comorbidity severity in their usual abstraction
of the medical record.7
Statistical Analysis
Descriptive statistics were used to describe the patients’ character-
istics and outcomes. Normally distributed continuous data are
expressed as mean ± SD throughout. Medians with ranges are used
when continuous data are not normally distributed. Categorical
data are expressed as counts and proportions. The χ2 or Fisher
exact test was used to analyze the categorical data. Kaplan-Meier
(product-limit) graphs were used to demonstrate survival with
time and freedom from recurrence of disease. Survival and event-
free survival comparisons between groups of patients were com-
pleted with the Mantel-Haenszel log rank test. Cox multivariate
proportional hazards regression methods were used to discrimi-
nate independent risk factors for death after surgical resection for
stage I NSCLC. Time to death after operation was selected as the
primary outcome. The likelihood ratio method was used to deter-
mine hazard ratios, and the hazard ratio was used to approximate
the relative risk.
All data analysis was performed with Systat (Systat 10.0 for
Windows; SPSS Inc, Chicago, Ill).
Results
Patient Demographic Characteristics
Four hundred fifty-one patients with pathologic stage I
NSCLC (T1 N0 M0 or T2 N0 M0) underwent surgical
resection between January 1, 1994, and December 31, 1999
(Table 2). Two hundred forty-nine (55%) patients were
male and 202 (45%) were female. The mean age was 64.4
± 10.5 years. The distribution of overall comorbidity sever-
ity was as follows: none, 142 (31.5%); mild, 150 (33.3%);
moderate, 115 (25.5%); and severe, 44 (9.8%).
Two hundred fifty patients (55%) had T1 tumors and 201
patients (45%) had T2 tumors. Adenocarcinoma was the most
common histologic variant (46%). Four hundred nineteen
patients (93%) underwent anatomic resection. Most patients
(82%) underwent lobectomy for treatment of their NSCLC.
However, 38 patients (8%) required a more extensive opera-
tion to ensure complete resection. Forty-four patients (10%)
with T1 lesions underwent limited pulmonary resection by
segmentectomy (3%) or wedge excision (7%).
Survival
Survival data were collected for each patient from the date
of operation, with a mean duration of follow-up of 35.7
months. The 3-year actuarial survival for the entire group
was 76.4%. The 3-year actuarial survival of patients with
T2 tumors (71.4%) was lower than that of patients with T1
tumors (80.4%). However, this difference was not statisti-
cally significant (Figure 1). When patients were stratified
according to comorbidity severity, there was a significant
relationship between comorbidity severity and survival (P <
.002, Figure 2).
The association of comorbidity severity and survival was
analyzed by multivariate Cox regression analysis. The addi-
tional variables of T status, age, gender, and tumor histo-
logic type (Table 3) were included in the model. Patients
Figure 1. Three-year actuarial survival of the entire group strati-
fied by stage IA and stage IB.
Figure 2. Three-year actuarial survival stratified by comorbidity
severity.
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with mild comorbidity severity had a slightly increased risk
of death in the follow-up period relative to patients with a
comorbidity severity of none, although this difference did
not achieve statistical significance (relative risk 1.44, 95%
confidence interval 0.89-2.34, P = .14). However, patients
with moderate comorbidity severity (relative risk 2.28, 95%
confidence interval 1.43-3.65, P = .001) and severe comor-
bidity severity (relative risk 1.94, 95% confidence interval
1.023-3.70, P = .042) were approximately twice as likely to
die during the follow-up period as were patients with no
comorbidity. There was no significant association of T sta-
tus, age, gender, or tumor histologic type with survival.
Causes of Death
One hundred twenty-eight patients (28%) died during the
follow-up period (Table 4). Ten patients (2.2%) died in the
immediate postoperative period. Although there was a trend
toward higher operative mortality among patients with more
severe comorbidity, this did not achieve statistical signifi-
cance (P = .055). The proportion of patients who died from
recurrent disease did not differ across comorbidity severity
classification (P = .92). However, the proportion of patients
who died from causes other than recurrent lung cancer was
significantly higher among patients with increasing comor-
bidity severity (P < .001).
Causes of Death Other than Recurrent Lung Cancer
Of the 118 patients who died during the follow-up period,
68 (57%) died of causes other than recurrent lung cancer
(Table 5). The most common cause of death was cardiac
disease, followed by death from a second malignancy.
Respiratory failure, cerebrovascular disease, sepsis, pul-
monary embolism, motor vehicle crashes, and diabetes
were also causes of death in this group of patients.
Fifty-two patients had new primary malignancies
develop after resection of NSCLC (Table 6). The most com-
mon second malignancy encountered was NSCLC.
Although it is often difficult to differentiate a second pri-
mary tumor from an isolated pulmonary metastatic focus,
13 of 23 second primary lung tumors had a different histo-
logic type at the time of diagnosis. The remaining 10
patients had isolated contralateral tumors with no other evi-
dence of disease. In addition, pathologic examination sug-
gested a primary carcinoma rather than a contralateral
hematogenous metastasis.
Incidence of Recurrent Lung Cancer
Seventy-one patients (15.7%) had recurrent NSCLC during
the follow-up period. The rates of recurrence as a function
of comorbidity severity were as follows: none, 15.4% (n =
22/142); mild, 16.7% (n = 25/150); moderate, 16.5% (n =
19/115); and severe, 11.4% (n = 5/44, P = .85). The recur-
rence-free 3-year survival of patients with T2 tumors was
significantly lower than that of patients with T1 tumors (P
= .01, Figure 3).
Discussion
Patients with NSCLC often have serious comorbidity at the
time of diagnosis. In addition to atherosclerotic cardiovas-
cular disease and chronic obstructive pulmonary disease,
many of these patients also have chronic renal insufficiency,
diabetes mellitus, a history of a previously treated malig-
nancy, or morbid obesity. Because 5-year survival is a stan-
dard measure for the effectiveness of lung cancer treatment
in this disease, it is critical to understand the impact of
comorbidity on survival after the surgical treatment of
NSCLC.
TABLE 3. Results of multivariate analysis of prognostic
factors influencing survival
Relative Confidence P
Variable No. risk 95% interval value
Comorbidity severity
None 142 1.000 — —
Mild 150 1.441 0.887-2.342 .140
Moderate 115 2.284 1.430-3.651 .001
Severe 44 1.944 1.023-3.699 .042
T status
T1 250 1.000 — —
T2 201 1.365 0.957-1.944 .086
Age (y) 451 1.017 0.997-1.037 .088
Gender
Female 202 1.000 — —
Male 249 1.190 0.995-1.120 .349
Histologic type
Other 242 1.000 — —
Adenocarcinoma 209 0.921 0.646-1.312 .649
Figure 3. Three-year disease-free actuarial survival stratified by
stage IA and stage IB.
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The importance of comorbidity in patients with lung and
other cancers was initially identified by Feinstein and col-
leagues more that thirty years ago.8-13 The original goal of
their research was to examine the impact of different cancer
treatments on prognosis. However, they observed that a sig-
nificant proportion of patients with localized cancer had
poor outcomes, whereas other patients with more advanced
stages had satisfactory outcomes. Careful review of the
medical records demonstrated that patient-based factors of
cancer-related symptom severity and comorbidity explained
much of the discrepancy between TNM stage and patient
outcome.14 Other investigators have confirmed the impor-
tance of comorbidity in the outcome of patients with can-
cers at other anatomic sites.15-21
In this analysis comorbidity severity had a significant
negative impact on survival after surgical resection among
patients with stage I NSCLC. After controlling for age, gen-
der, T status, and tumor histologic type in a multivariate
analysis, the relative risk of mortality as a function of comor-
bidity was 2 times higher among patients with moderate and
severe comorbidity than among patients with no comorbid-
ity. The higher risk of death was attributable to the comorbid
conditions, because the proportion of patients who died of
causes other than recurrent lung cancer was significantly
higher among those with moderate and severe comorbidity.
The data from this analysis demonstrate the influence of
comorbidity on survival in patients treated for stage I
NSCLC and validate the ability of the modified KFI to strat-
ify comorbidity severity. These findings have important
implications in the development of future clinical trials that
attempt to evaluate the effectiveness of various therapies in
the treatment of patients with NSCLC. If patients with mod-
erate and severe comorbidity are to be included in these
clinical trials, it is important to stratify the analysis accord-
ing to comorbidity when reporting 5-year survivals, because
these patients often die of causes other than recurrent lung
cancer. An alternative, less desirable because as many as
35% of patients with stage I NSCLC have moderate or
severe comorbidity, would be to exclude such patients from
participation in these trials. The eligibility criteria for many
current clinical trials include the assessment of performance
status according to either the Karnofsky index or the
Eastern Cooperative Oncology Group performance scale.
These measures of performance status address the activity
levels of individual patients and are often influenced by a
patient’s motivation and social support. In contrast, deter-
mination of comorbidity severity provides a more objective
measure of a patient’s physiologic reserve before the initia-
tion of treatment.
Because the overall 5-year survival for patients with
stage IB tumors (T2 N0 M0) is approximately 55%,5 there
has been increasing enthusiasm for including these patients
in clinical trials to assess the efficacy of neoadjuvant
(Intergroup S9900) or adjuvant (Intergroup 9633) chemo-
therapy. However, the data from this analysis demonstrated
that most deaths in this group occurred as the result of
TABLE 4. Causes of death for the 128 patients stratified by preoperative comorbidity score
Preoperative comorbidity None (n = 142) Mild (n = 150) Moderate (n = 115) Severe (n = 44) P value
Operative mortality 1 (0.7%) 5 (3.3%) 1 (0.9%) 3 (6.8%) .055
Recurrent cancer 16 (11.3%) 16 (10.7%) 14 (12.2%) 4 (9.1%) .922
Other 12 (8.5%) 18 (12.0%) 31 (26.9%) 7 (15.9%) <.001
TABLE 5. Causes of death of patients who died as a result
of factors unrelated to resection or recurrence of the pri-
mary NSCLC
Cause of death No.
Cardiac failure 18
Other malignancy 17
Respiratory failure 10
Cerebrovascular accident 5
Sepsis 4
Pulmonary embolism 3
Motor vehicle crash 3
Diabetes 3
Other 5
Total 68
TABLE 6. New primary malignancies after initial resection
Location of new primary tumor No.
Lung 23
Head and neck 6
Prostate 5
Gastric or esophageal 3
Bladder or kidney 3
Breast 2
Bone 2
Pancreas 2
Colon 2
Other 4
Total 52
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causes other than recurrent lung cancer. In this analysis only
22% of patients with T2 tumors had recurrence and thus
would potentially benefit from neoadjuvant or adjuvant
chemotherapy. Because chemotherapy treatment has associ-
ated toxic side effects, patients with moderate or severe
comorbidity severity might not ever be eligible for inclusion
in these clinical trials, bringing the number of patients who
could possibly benefit from this therapy even lower.
If chemotherapy treatment were able to reduce the recur-
rence rate from 22% to 11% (50% risk reduction), then 9
patients would need to receive chemotherapy to prevent
recurrence in 1 patient (according to the number to treat
analysis).22 If chemotherapy treatment were only able to
reduce the recurrence rate from 22% to 16.5% (25% risk
reduction), then 18 patients would need to receive
chemotherapy to prevent recurrence in 1 patient. According
to this analysis, demonstrating the efficacy of neoadjuvant
or adjuvant chemotherapy in decreasing tumor recurrence
for patients with stage I NSCLC will be difficult unless this
therapy can be demonstrated to reduce the risk of recur-
rence by more than 50%. The findings from this study have
important implications for the design and accrual of these
clinical trials.
The care management of patients with NSCLC remains
a significant challenge. Many patients have significant
comorbidity that adversely affects overall survival.
Anatomic resection of stage I NSCLC results in excellent
tumor-free survival and remains the standard form of ther-
apy. Efforts to improve survival after treatment of NSCLC
will need to be directed both toward reducing the incidence
of recurrent disease and toward optimizing the management
of coexisting medical illnesses.
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Discussion
Dr John R. Roberts (Nashville, Tenn). This study is directed
toward an important problem in cancer research: how patients’
other diseases and illnesses may affect survival. This issue is par-
ticularly important for thoracic malignancies, because patients
with lung and esophageal cancer often have other illnesses, such
as emphysema, hypertension, and coronary disease. As oncolo-
gists, we are commonly told that surgery fails to cure early lung
cancer 40% of the time, if we take Mountain’s data,1 but we do not
know from such studies what percentage of patients actually die of
diseases other than recurrence of the malignancy. Obviously, treat-
ments directed toward preventing cancer recurrence would not
decrease the death rate from unrelated diseases.
Surgeons have been accustomed to using at least three types of
illness scales in evaluating a patient’s response to disease or treat-
ments. Acute injury scales, such as the Acute Physiology and
Chronic Health Evaluation system, attempt to measure the sever-
ity of an acute injury such as occurs in trauma. Oncologists are
accustomed to using performance scales, such as the Karnofsky
and Eastern Cooperative Oncology Group scales, and rating sys-
tems that assess a patient’s functional capacity to work and to per-
form daily activities. These have been validated for treatment of
patients with chemotherapy, but they only indirectly measure the
effects of comorbid illnesses. Probably less common are comorbid
index systems that measure two aspects of a patient’s health,
health irrespective of cancer and the impact of cancer on their
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health as measured by symptoms, such as the modified KFI
described by Battafarano and coworkers.
I really have only two questions. First, Dr Battafarano, you
took great care in measuring the comorbid status of patients with
lung cancer. Do you also have data about other more commonly
used performance scales in oncology, such as the Eastern
Cooperative Oncology Group and Karnofsky scales? They should
intersect somewhat with measures of comorbidity, and it would be
interesting to see how those data vary.
Second, would not disease-free survival or perhaps freedom
from recurrence get at the same issue that you have touched on in
talking about comorbidity studies? That is, we want to know what
fraction of patients actually die of the cancer to optimize cancer
therapy, as opposed to being confused by the fraction of patients
who die of other problems.
Reference
1. Mountain CF. Revisions in the International System for Staging Lung
Cancer. Chest. 1997;111:1710-7.
Dr Robert J. Ginsberg (Toronto, Ontario, Canada). We have
to be careful about a few things. Only half the patients reached the
3-year follow-up mark, so we do not have the usual 5-year assess-
ment of recurrence.
In your article you did not discuss how unusual the number of
noncancer deaths were in this series compared to most series,
which usually quote a figure of 20% of deaths as noncancer
deaths, whereas in your series the figure was 60%. How do you
explain that? Maybe things have changed.
I also would like you to address the fact that you are discussing
patients with pathologic T2 tumors, suggesting that they are not
candidates for, for instance, neoadjuvant therapy, whereas in the
neoadjuvant protocols it is not pathologic staging that we discuss
but clinical staging. We know from past experience at least that
only 40% of patients with clinically staged T2 N0 disease survive
5 years, because half of them do not have T2 N0 disease accord-
ing to pathologic examination.
The other area in your article was your discussion of clinical
trials and the cost-benefit reality of clinical trials with respect to
patient tolerance. If we can cure 1 in 10 of these patients by the
addition of combined modality therapy, considering the fact there
are 40,000 people in the United States who have this stage of dis-
ease, we are doing pretty well.
Dr Scott J. Swanson (Boston, Mass). I have a question about
the respiratory failure group. Respiratory failure was the third
highest noncancer cause of death. Do you have any details on that?
Was it early or late, and was it related to preoperative forced expi-
ratory volume in 1 second?
Dr Richard I. Whyte (Stanford, Calif). I noticed when reading
the abstract that you took these patients during a 5-year period of
time, and we are repeatedly hearing how patients who are having
operations for lung cancer are getting older and sicker. Were you
able to see any difference between the beginning of that 5-year
study in 1994 and the end in 1999?
Dr Battafarano. With respect to Eastern Cooperative
Oncology Group and Karnofsky performance scores, we did not
specifically look at them in direct comparison with comorbidity
severity scores. I think that one advantage of comorbidity severity
scores is that they provide a more detailed analysis, rather than
merely determining whether people are able to meet the demands
of activities of daily living. However, I do not have direct compar-
isons between Eastern Cooperative Oncology Group scores or
Karnofsky performance scores and comorbidity scores.
With respect to the incidence of recurrent lung cancer, it was
approximately 16% across all four comorbidity severity determina-
tions and did not differ among them. We plotted disease-free sur-
vival curves across comorbidity severity, but they did not show any
differences. That is why we did not include them in the article.
Dr Ginsberg, you were saying that only half of the patients
reached the 3-year follow-up mark and so we did not have 5-year
survival data for this population. I think that this is a unique pop-
ulation. As you know, at Barnes we have a respiratory failure pro-
gram, and that is where some of these patients’ cancers were
identified. I think that our population is therefore more heavily
skewed with patients with moderate and severe comorbidity than
the average clinical trial, from which many of these people would
be excluded. More than half of all deaths resulted from causes
other than recurrent lung cancer. I think that this is because we
operated on patients with moderate and severe comorbidity,
whereas in other series those patients have often been excluded or
did not represent as high a proportion as in our population.
With respect to the chemotherapy, there are two issues there.
One trial is sponsored by the Cancer and Leukemia Group B
(CALGB), and it is an intergroup protocol in which they actually
enrolled patients with T2 N0 tumors after pathologic staging, so
that would be an adjuvant trial. The Bimodality Lung Oncology
Trial includes people with clinically staged T2 N0 disease, which
indeed may prove to be T2 N1, and this would be a neoadjuvant
trial. There is a difference, and I think that maybe these data would
be more applicable to the CALGB-sponsored clinical trial, in
which they are looking at adjuvant therapy.
I do not believe that this was a cost-benefit analysis. We men-
tioned in the article that if only 22% of patients with T2 N0 dis-
ease had recurrence and there was a 50% risk reduction from
chemotherapy in the development of recurrent disease, then you
would have to treat 9 patients to prevent 1 patient from getting
recurrent lung cancer. If your risk reduction is only 25%, you
would have to treat 18 patients. I think that this is important
because the number of patients that had recurrent lung cancer, at
least in this series, was lower than we would normally expect from
the Mountain data.1
Dr Swanson, you wondered about the respiratory failure after-
ward. I do not have all the specifics. A lot of it was from pneumonia.
I do not know whether that was early, within the first 3 postoperative
months, or was during the 3-year follow-up period. We do not have
any specific data to look at correlation with forced expiratory volume
in 1 second, although that would be important to know.
Dr Whyte, you asked whether the patients tended to be sicker
later during that 5-year period. I could not tease out that informa-
tion with just this limited analysis. However, we will look back at,
for example, a cohort of patients from 1990 to 1995 and compare
it with our cohort here, and that might be important.
Reference
1. Mountain CF. Revisions in the International System for Staging Lung
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Dr David J. Sugarbaker (Boston, Mass). In this cohort of
patients during this period, did you exclude some patients, or is
this your entire cohort of patients with stage I NSCLC?
Dr Battafarano. A total of 480 patients underwent resection,
and 451 of them were included in this analysis.
Dr Sugarbaker. And 29 were excluded because they were
unavailable for follow-up?
Dr Battafarano. No, they were excluded because they did not
have comorbidity scores determined prospectively.
Dr Sugarbaker. You made a point about the risk adjustment. In
terms of this category of patient with the addition of either adjuvant
or neoadjuvant chemotherapy, given the impact here of your comor-
bidities, could you just address the feasibility of this situation?
Dr Battafarano. I think that in most clinical trial studies
right now patients with moderate and severe comorbidity would
be excluded from participation just on the basis of their comor-
bid illnesses. These patients represent a third of those with
NSCLC, and we must either somehow stratify according to
comorbidity or continue to exclude them from participation in
trials.
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